Prot# CC-5013-CLL-002: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid) as Maintenance Therapy for Patients with B-Cell Chronic Lymphocytic Leukemia Following

Project: Research project

Project Details

StatusFinished
Effective start/end date6/14/106/30/11

Funding

  • Celgene Corporation (CC-5013-CLL-002)